Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results

By Dr. Matthew Watson

Raised $83.6 million in gross proceeds from common stock offeringSTOPS™ and CAM programs: initial data presented at conferences, dosing in 2nd CHB cohorts ongoingClinical trial application filed for 3rd CHB drug candidate ALG-0202572 (antisense oligonucleotide) – dosing in HVs anticipated in Q4 2021

Read more here:
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results

Related Post


categoriaGlobal News Feed commentoComments Off on Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results | dataAugust 6th, 2021

About...

This author published 4012 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research